PMID- 29420073
OWN - NLM
STAT- MEDLINE
DCOM- 20190926
LR  - 20200306
IS  - 1097-9891 (Electronic)
IS  - 0095-2990 (Print)
IS  - 0095-2990 (Linking)
VI  - 44
IP  - 6
DP  - 2018
TI  - Open-label pilot study of injectable naltrexone for cannabis dependence.
PG  - 619-627
LID - 10.1080/00952990.2017.1423321 [doi]
AB  - BACKGROUND: There are no FDA-approved pharmacotherapies for cannabis use 
      disorders (CUD), despite the evaluation of numerous medications. Notably, chronic 
      dosing of oral naltrexone decreases self-administration of cannabis in human 
      laboratory studies. OBJECTIVES: To test the feasibility of long-acting injectable 
      naltrexone for the treatment of CUD, while obtaining preliminary safety and 
      efficacy data. METHODS: Twelve adult participants (seven male) meeting DSM-IV-TR 
      criteria for cannabis dependence enrolled into an 8-week, open-label pilot study 
      conducted at an academic treatment research clinic. They received 380 mg 
      intramuscular injections of long-acting naltrexone on study day 1 and at the 
      start of study week 5. Outcome measures included percentages of study completers 
      and participants who received the second injection, frequency of adverse events 
      (AEs), and cannabis consumption measured by average daily grams, dollars, and 
      using days per week as measured by timeline follow-back and urine oral 
      delta-9-tetrahydrocannabinol (THC) concentrations. RESULTS: Of the 12 
      participants enrolled in the study, 9 completed the study and 6 received the 
      second injection. There were no severe AEs but an unexpected AE led to the 
      addition of supportive medications to the protocol. Number of cannabis use days 
      per week significantly decreased over the course of the study (p = .001). 
      Creatinine-corrected urine THC concentrations and average daily cannabis use per 
      study week in grams and in dollars did not decrease over the course of the study. 
      CONCLUSIONS: Long-acting injectable naltrexone is a feasible intervention for CUD 
      worthy of further study in a placebo-controlled, double-blinded randomized 
      clinical trial.
FAU - Notzon, Daniel P
AU  - Notzon DP
AD  - a Division on Substance Abuse , New York State Psychiatric Institute , New York , 
      NY , USA.
AD  - b Department of Psychiatry , College of Physicians and Surgeons, Columbia 
      University , New York , NY , USA.
FAU - Kelly, Meredith A
AU  - Kelly MA
AD  - a Division on Substance Abuse , New York State Psychiatric Institute , New York , 
      NY , USA.
AD  - b Department of Psychiatry , College of Physicians and Surgeons, Columbia 
      University , New York , NY , USA.
FAU - Choi, C Jean
AU  - Choi CJ
AD  - c Division of Biostatistics , New York State Psychiatric Institute , New York , 
      NY , USA.
FAU - Pavlicova, Martina
AU  - Pavlicova M
AD  - d Department of Biostatistics , Mailman School of Public Health, Columbia 
      University , New York , NY , USA.
FAU - Mahony, Amy L
AU  - Mahony AL
AD  - a Division on Substance Abuse , New York State Psychiatric Institute , New York , 
      NY , USA.
FAU - Brooks, Daniel J
AU  - Brooks DJ
AD  - a Division on Substance Abuse , New York State Psychiatric Institute , New York , 
      NY , USA.
FAU - Mariani, John J
AU  - Mariani JJ
AD  - a Division on Substance Abuse , New York State Psychiatric Institute , New York , 
      NY , USA.
AD  - b Department of Psychiatry , College of Physicians and Surgeons, Columbia 
      University , New York , NY , USA.
FAU - Levin, Frances R
AU  - Levin FR
AD  - a Division on Substance Abuse , New York State Psychiatric Institute , New York , 
      NY , USA.
AD  - b Department of Psychiatry , College of Physicians and Surgeons, Columbia 
      University , New York , NY , USA.
LA  - eng
GR  - K24 DA029647/DA/NIDA NIH HHS/United States
GR  - T32 DA007294/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20180208
PL  - England
TA  - Am J Drug Alcohol Abuse
JT  - The American journal of drug and alcohol abuse
JID - 7502510
RN  - 0 (Narcotic Antagonists)
RN  - 5S6W795CQM (Naltrexone)
SB  - IM
MH  - Adult
MH  - Female
MH  - Humans
MH  - Injections, Intramuscular
MH  - Male
MH  - Marijuana Abuse/*drug therapy
MH  - Middle Aged
MH  - Naltrexone/administration & dosage/*therapeutic use
MH  - Narcotic Antagonists/administration & dosage/*therapeutic use
MH  - Pilot Projects
MH  - Treatment Outcome
PMC - PMC6082728
MID - NIHMS947015
OTO - NOTNLM
OT  - Cannabis
OT  - marijuana
OT  - medication
OT  - pilot
OT  - treatment
COIS- Declaration of Interest Dr. Notzon, Dr. Kelly, Ms. Choi, Dr. Pavlicova, Dr. 
      Mariani, Amy Mahony and Daniel Brooks have no disclosures. Dr. Levin served as a 
      consultant to GW Pharmaceuticals and to Eli Lilly, and served on an advisory 
      board to Shire in 2005-2007.
EDAT- 2018/02/09 06:00
MHDA- 2019/09/27 06:00
PMCR- 2018/09/06
CRDT- 2018/02/09 06:00
PHST- 2018/02/09 06:00 [pubmed]
PHST- 2019/09/27 06:00 [medline]
PHST- 2018/02/09 06:00 [entrez]
PHST- 2018/09/06 00:00 [pmc-release]
AID - 10.1080/00952990.2017.1423321 [doi]
PST - ppublish
SO  - Am J Drug Alcohol Abuse. 2018;44(6):619-627. doi: 10.1080/00952990.2017.1423321. 
      Epub 2018 Feb 8.